United Therapeutics (UTHR) Change in Accured Expenses (2009 - 2026)

United Therapeutics has disclosed Change in Accured Expenses across 18 years of filings, most recently posting -$4.0 million for Q2 2026.

• In Q2 2026, Change in Accured Expenses fell 108.68% year-over-year to -$4.0 million; the TTM figure through Jun 2026 stood at $37.7 million (down 35.56% YoY), while the FY2025 annual figure was $97.9 million, up 129.27% from the prior year.
• Change in Accured Expenses came in at -$4.0 million for Q2 2026 at United Therapeutics, up from -$12.7 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $46.1 million in Q2 2025 to a low of -$23.1 million in Q4 2023.
• Average Change in Accured Expenses over 5 years is $12.5 million, with a median of $15.7 million recorded in 2022.
• Year-over-year, Change in Accured Expenses jumped 228.89% in 2025 and plunged 388.46% in 2026.
• Over 5 years, Change in Accured Expenses stood at $9.1 million in 2022, then tumbled by 353.85% to -$23.1 million in 2023, then grew by 22.08% to -$18.0 million in 2024, then jumped by 228.89% to $23.2 million in 2025, then slumped by 117.24% to -$4.0 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$4.0 million in Q2 2026, -$12.7 million in Q1 2026, and $23.2 million in Q4 2025.